02.12.2010 • NewsLanxession exchange resinsIndia

Lanxess Opens New Plant for Ion Exchange Resins in India

Today, specialty chemicals group Lanxess opened Asia's most state-of-the-art plant for ion exchange resins in India.

The new plant was constructed over a period of two years in the new chemical park in Jhagadia in the Indian state of Gujarat. It boasts an annual capacity of 35,000 metric tons.

Around 200 employees from the Ion Exchange Resins (ION) business unit manufacture products for industrial water treatment for the semi-conductor and pharmaceutical industries, the food sector and the power industry.

The opening marked the successful completion of the second expansion phase in Jhagadia. The first project phase, which was completed in March of this year, saw a rubber chemicals production plant taken into operation.

Overall, Lanxess has invested around €50 million in the site to date.

"Demand for clean water is set to increase by around one-third worldwide by 2030. In Asia in particular, and in India especially, demand will grow disproportionately due to rapid population growth and increasing urbanization," said Chairman of the Lanxess Board of Management Axel C Heitmann at the official opening ceremony, which was also attended by the State Premier of the Indian state of Gujarat. "Production has therefore started at exactly the right time to benefit from this development."

Company

Logo:

LANXESS Deutschland GmbH

Kennedyplatz 1
50569 Köln
Germany

Company contact







Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.